COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM

被引：0
|
作者：
Holanda, P. [1 ]
Salgado De Santana, C. [2 ]
Senna, T. [1 ]
Carmo, L. [1 ]
Alexandre, R. F. [1 ]
机构：
[1] Pfizer Inc, Sao Paulo, Brazil
[2] Pfizer Inc, Santos, SP, Brazil
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI11
引用
收藏
页码：S96 / S96
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis
    Punekar, Yogesh Suresh
    Hawkins, Neil
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2010, 11 (01) : 67 - 76
  • [22] Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis
    Yogesh Suresh Punekar
    Neil Hawkins
    The European Journal of Health Economics, 2010, 11 : 67 - 76
  • [23] Performing a cost-effectiveness analysis: Surveillance of patients with ulcerative colitis
    Provenzale, D
    Wong, JB
    Onken, JE
    Lipscomb, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (06) : 872 - 880
  • [24] Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system
    Bahia, Luciana Ribeiro
    Araujo, Denizar Vianna
    Pepe, Camila
    Trindade, Michelle
    Camargo, Caroline Mendonca
    Javaroni, Valter
    INTERNATIONAL BRAZ J UROL, 2012, 38 (05): : 595 - 605
  • [25] Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective
    Mishra, Shubhra
    Jena, Anuraag
    Kakadiya, Rinkalben
    Sharma, Vishal
    Ahuja, Vineet
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (08) : 737 - 752
  • [26] Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany
    Sardesai, Aditya
    Dignass, Axel
    Quon, Peter
    Milev, Sandra
    Cappelleri, Joseph C.
    Kisser, Agnes
    Modesto, Irene
    Sharma, Puza P.
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 279 - 290
  • [27] Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates in the Tofacitinib Ulcerative Colitis Clinical Program
    Winthrop, Kevin L.
    Loftus, Edward V., Jr.
    Baumgart, Daniel C.
    Salese, Leonardo
    Thorpe, Andrew J.
    Lawendy, Nervin
    Chan, Gary
    Pedersen, Ronald D.
    Reinisch, Walter
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S427 - S429
  • [28] ECONOMIC EVALUATION OF INFLIXIMAB FOR TREATMENT OF REFRACTORY ULCERATIVE COLITIS IN IRAN: COST-EFFECTIVENESS ANALYSIS
    Moradi, N.
    Tofighi, S.
    Zanganeh, M.
    Akbari Sari, A.
    Zarei, L.
    VALUE IN HEALTH, 2015, 18 (07) : A628 - A628
  • [29] COST-EFFECTIVENESS ANALYSIS OF NETUPITANT/ PALONOSETRON FOR CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Araujo, G.
    Silva, H. M.
    Picoli, R. M.
    VALUE IN HEALTH, 2023, 26 (12) : S93 - S93
  • [30] COST-EFFECTIVENESS OF FREMANEZUMAB FOR THE TREATMENT OF MIGRAINE IN ENGLAND FROM A HEALTHCARE SYSTEM PERSPECTIVE
    Skroumpelos, A.
    Freddi, M.
    Akcicek, H.
    Cohen, J. M.
    Driessen, M. T.
    VALUE IN HEALTH, 2021, 24 : S160 - S160
12345